**Name of journal: World Journal of Gastrointestinal Pathophysiology**

**ESPS Manuscript NO: 9447**

**Columns: TOPIC HIGHLIGHT**

WJGP 5th Anniversary Special Issues (1): *Helicobacter pylori*

Treatment of *Helicobacter oylori* infection: Past, present and future

PapastergiouV *et al.* Treatment of *Helicobacter pylori* infection

Vasilios Papastergiou, Sotirios D Georgopoulos, Stylianos Karatapanis

**Vasilios Papastergiou, Stylianos Karatapanis,** Department of Internal Medicine, General Hospital of Rhodes, 85100 Rhodes, Greece

**Sotirios D Georgopoulos,** Department of Gastroenterology, Athens Medical, P. Faliron Hospital, 17562 Athens, Greece

**Author contributions:** Papastergiou V contributed to conception and design, drafting the article; Georgopoulos SD contributed to drafting the article, revising the article critically for important intellectual content; Karatapanis S contributed to final approval of the version to be published.

**Correspondence to:** **Stylianos Karatapanis, MD, PhD,** Department of Internal Medicine, General Hospital of Rhodes, 10 Kalopetras Str, 85100 Rhodes, Greece. stylkar@otenet.gr

**Telephone:** +30-22410-80456 **Fax:** +30-22410-66410

**Received:** February 12, 2014  **Revised:** April 15, 2014

**Accepted:** July 17, 2014

**Published online:**

**Abstract**

*Helicobacter pylori (H. pylori)* is a major human pathogen associated with significant morbidity and mortality. However, after decades of efforts, treatment of *H. pylori* remains a challenge for physicians, as there is no universally effective regimen. Due to the rising prevalence of antimicrobial resistance, mainly to clarithromycin, efficacy of standard triple therapies has declined to unacceptably low levels in most parts of the world. Novel regimens, specifically experimented to improve the therapeutic outcome against antibiotic-resistant *H. pylori* strains, are now recommended as first-line empirical treatment options providing high efficacy (reportedly > 90% in intention to treat analysis) even in high clarithromycin resistance settings. These include the bismuth quadruple, concomitant, sequential and hybrid therapies. Due to the rapid development of quinolone resistance, levofloxacin-based regimens should be reserved as second-line/rescue options. Adjunct use of probiotics has been proposed in order to boost eradication rates and decrease occurrence of treatment-related side effects. Molecular testing methods are currently available for the characterization of *H. pylori* therapeutic susceptibility, including genotypic detection of macrolide resistance and evaluation of the cytochrome P450 2C19 status known to affect the metabolism of proton pump inhibitors. In the future, use of these techniques may allow for culture-free, non-invasive tailoring of therapy for *H. pylori* infection.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Helicobacter pylori; Antibiotic resistance; Bismuth-quadruple; Concomitant; Sequential; Probiotics

**Core tip:** Worldwide increase in prevalence of macrolide resistance has accounted for the failure of standard therapies for the treatment of *Helicobacter pylori (H. pylori)* infection. Bismuth quadruple, concomitant, sequential and hybrid therapies are now recommended as first-line empirical treatments providing improved efficacy in high clarithromycin resistance settings. As quinolone resistance is rapidly increasing, levofloxacin should be preferentially used in second-line/rescue therapies. There is increasing evidence that adjunct probiotic supplementation improves the therapeutic outcome and tolerability. Genotypic characterization of *H. pylori* susceptibility to therapy may allow for a tailored therapeutic approach in the future.

Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of *Helicobacter pylori* infection: Past, present and future. *World J Gastrointest Pathophysiol* 2014; In press

**INTRODUCTION**

Treatment of *Helicobacter pylori* (*H. pylori*) infection is paramount for the management of prevalent gastrointestinal diseases, including peptic ulcer disease, gastric cancer and functional dyspepsia[[1-3](#_ENREF_1)]. Moreover, extra-digestive disorders are now included as indications for eradication of*H. pylori*: idiopathic thrombocytopenic purpura, vitamin B12 deficiency and unexplained iron deficiency anemia[[4](#_ENREF_4)]. Contrarily to other bacterial infections, for which susceptibility testing is commonly performed to guide treatment, culture of *H. pylori* is not widely available and requires performing endoscopy which is not well-tolerated by all patients and has a series of limitations, including the fact that *in vitro* susceptibility does not always guarantee *in vivo* eradication[[5](#_ENREF_5)]. Hence, regimens for *H. pylori* have been routinely prescribed empirically, provided they have been previously tested and sufficiently tailored with regard to various parameters (i.e.; treatment dose, duration, dosing intervals etc.) to optimize cure rates and minimize side effects. However, the optimal treatment to eradicate *H. pylori* remains to be established, as no regimen is effective universally. Worldwide increase in resistance to key antibiotics, mainly clarithromycin (CAM), but also metronidazole (MNZ) and levofloxacin, is the main determinant of failure in the treatment of *H. pylori* infection[[6](#_ENREF_6), [7](#_ENREF_7)]. In a recent systematic review, the global incidence of CAM resistance has been reported to be 17.2% ranging from 11.1% in Europe to 29.3% in America, whereas, in the same analysis, continental rates of resistance to MNZ were 17% and 44.1% respectively[[8](#_ENREF_8)]. Antibiotic consumption for infections other than *H. pylori* is accounting for the wide increase in *H. pylori* antibiotic resistance rates[[9](#_ENREF_9), [10](#_ENREF_10)]. Indeed, different national policies for antibiotic use are largely reflecting geographical distribution of *H. pylori* resistance: CAM resistance has been reported to be significantly higher in SouthernEuropean countries (reaching 49% in some areas of Spain) as compared to Northern Europe (*e.g.,* only 1% in the Netherlands) where policies for antibiotic use are more stringent[[9](#_ENREF_9)]. Additionally to the development of antibiotic resistance, a series of both host and pathogen related factors may negatively impact on the performance of regimens to eradicate *H. pylori* (Table 1)[[11](#_ENREF_11), [12](#_ENREF_12)]. Despite decades of efforts, treatment of *H. pylori* infection remains a challenging issuefor both researchers and practicing physicians. In the present article we aimto provide a comprehensive overview of perspectives on the past, present and future of *H. pylori* eradication.

**CLARITHROMYCIN-BASED TRIPLE THERAPIES: A DECLINING CLINICAL STANDARD**

Historically, the first truly effective therapy for *H. pylori* infection, comprising of bismuth, tetracycline and MNZ, was proposed in 1990[[13](#_ENREF_13)]. A few years later, use of CAM in a triple therapy, proposed by Bazzoli *et al*[[14](#_ENREF_14)], was the start of CAM-based triple regimens, thereafter representing the gold standard in the treatment of *H. pylori*. In studies conducted during the 90’s, standard triple therapies (STT) comprising of a proton pump inhibitor (PPI) *bid*, CAM 500 mg *bid* and amoxicillin 1000 mg *bid* or MNZ 500 mg (or 400 mg in England), all given for 7-14 days, provided consistently good results yielding > 80% eradication success and even > 90% was feasible[[15](#_ENREF_15), [16](#_ENREF_16)]. Due to this high efficacy and relative simplicity, optimal safety profile, and large pharmaceutical company commitment, these regimens have been widely accepted in national expert panels and consensus recommendations worldwide as standard of care treatments for first-line eradication of *H. pylori*[[17-20](#_ENREF_17)]. However, rising prevalence of CAM resistance has accounted for a significant decline in the efficacy of standard regimens. This decreasing efficacy was already evident in the meta-analyses published by the early 2000’s, prompting significant changes in the paradigm of treating the infection. These included the introduction of the concept of cumulative treatment efficacy (requiring the patient to comply with more treatment courses; thus, more side effects and spreading of secondary antibiotic resistance), and later the introduction of a local threshold (15%-20%) of CAM resistance at which CAM should not be used empirically[[17](#_ENREF_17), [18](#_ENREF_18)]. The decreased efficacy of standard treatments against CAM-resistant strains has been well-documented on a meta-analytic basis: In a meta-analysis by Fischbach and Evans, the success of triple therapy was decreased by 66.2% (95%CI: 58.2%-74.2%) when strains of *H. pylori* were resistant *vs* susceptible to CAM[[7](#_ENREF_7)]. Congruently, a more recent analysis by Venerito *et al*[[21](#_ENREF_21)], revealed similar results: including antimicrobial susceptibility data from 4 randomized clinical trials (RCTs), standard triple therapies successfully eradicated 88% of CAM-sensitive but only 14% of CAM-resistant *H. pylori* strains (risk difference = 0.75, 95%CI: 0.63-0.87). If MNZ is used, presence of MNZ resistance may also affect the therapeutic outcome[[22](#_ENREF_22)], although it is generally considered less important clinically. This is due to the fact that MNZ resistance may be largely overcome by increasing dose and prolonging treatment duration[[23](#_ENREF_23)]. Lastly, *H. pylori* resistance to amoxicillin is exceptional and generally **is not** relevant clinically. In the light of increasing data confirming suboptimal performance (< 70%) in most European countries, the recent Maastricht IV/ Florence consensus report has definitively displaced standard regimens as the empirical gold standard to eradicate *H. pylori*[[4](#_ENREF_4)]. Instead, use of legacy triple regimens should take into account the local resistance pattern (thus, used only in areas in which CAM resistance is < 20%) or rely on susceptibility testing provided that pre-treatment culture is available (*i.e.*, used as tailored treatments).

**CURRENT THERAPIES FOR *H. PYLORI* INFECTION**

Novel regimens, specifically experimented to improve the therapeutic outcome against antibiotic-resistant *H. pylori* strains, are now recommended as first-line empirical treatment options providing improved efficacy (reportedly > 90% in intention to treat analysis) in high CAM resistance settings. These regimens are summarized in Table 2.

**BISMUTH QUADRUPLE THERAPY**

Bismuth quadruple therapy (BQT) currently represents a preferred first-line treatments option for areas with a high (≥ 20%) incidence of CAM resistance but also a valuable second-line treatment option when a CAM-based regimen has previously failed. It works independently to CAM achieving > 90% eradication in the presence of CAM resistance, whereas implementation of a high MNZ dose (1500-1600 mg/d) and prolonged (10-14 d) treatment duration allow for minimizing the impact on MNZ resistance, providing eradication rates >85% even in regions with a high resistance to this drug[[24](#_ENREF_24)]. A patient-friendly monocapsule (containing bismuth, MNZ and tetracycline) is available (Pylera® , Aptalis, Mont St Hilaire, QC, Canada) providing ITT eradication rates of 86% and 80% in two large RCTs conducted in North America and Europerespectively[[25-27](#_ENREF_25)]. Contrarily, the ITT eradication rate with BQT was only 77.8% in a recent meta-analysis (*vs* 77% for STT), questioning both the efficacy as well as the superiority of the BQT over STT[[28](#_ENREF_28)]. However, a substantial grade of study heterogeneity, especially with respect to MNZ dosing, should be acknowledged. The second-line efficacy of BQT has been also confirmed on a meta-analytic basis (30 studies) showing an average 77% second-line efficacy (ITT) after failure of STT[[29](#_ENREF_29)]. Third-line efficacy of BQT after two previous eradication failures with CAM- and levofloxacin-containing triple therapies was 65% (ITT) in a multi-center study from Spain[[30](#_ENREF_30)]. Non-availability of bismuth salts or tetracycline in some countries as well as the potential toxicity of bismuth are the main limitations. However, including 4763 patients no differences with respect to tolerability were shown between non-bismuth and bismuth-containing groups except from dark stools being more common in the later[[31](#_ENREF_31)].

**SEQUENTIAL THERAPY**

Sequential therapy uses the same antibiotics contained in STT but administered sequentially. It has been postulated that the initial course of amoxicillin disrupts the bacterial cell wall preventing the development of efflux channels transferring CAM out of the bacteria [[32](#_ENREF_32)]. Although in the initial RCTs[[33](#_ENREF_33)] (most of them conducted in Italy) and earlier meta-analyses sequential therapy was clearly superior to STT [ITT eradication 91.7% (95%CI: 90%-93%) *vs* 76.7% (95%CI: 75%-79%) for STT] [[34](#_ENREF_34)], more recent data from South America, Iran and Korea revealed lower eradication rates (< 80%)[[35-37](#_ENREF_35)]. Despite this sequential therapy seems to be fairly effective against CAM mono-resistant strains, being able to eradicate 72.8% of them, its efficacy against dual resistant (CAM and MNZ) strains was only 37% (range: 16.2% to 60.7%) when 8 studies with antibiotic susceptibility data were evaluated[[38](#_ENREF_38)]. Critically, sequential therapy was not superior to either a 14-day triple therapy (RR = 1, 95%CI: 0.94-1.06) or a bismuth-based therapy (RR = 0.99, 95%CI: 0.94-1.05) in an extensive evaluation of 46 RCTs [[38](#_ENREF_38)].

**NON-BISMUTH QUADRUPLE (CONCOMITANT) THERAPY**

A non-bismuth quadruple “concomitant” therapy is another valid first-line treatment option for areas with a high incidence of CAM resistance[[39](#_ENREF_39), [40](#_ENREF_40)]. In 19 studies (2070 patients) the overall eradication rate with concomitant therapy was 88% (95%CI: 85%-91%) and 91% when 3 outlying studies with inherently short treatment duration (3-5 d) were excluded [[41](#_ENREF_41)]. Indeed, treatment duration of at least 7 d has been shown to be necessary for the success of concomitant therapy[[42](#_ENREF_42)], whereas extra-prolonging treatment to 14 days combined with a high PPI dose (omeprazole 40 mg × 2) may further boost cure rates to > 95%, as revealed by a non-inferiority multi-center trial[[43](#_ENREF_43)]. An increased efficacy against dual resistant *H. pylori* strains has been proposed as themain strength of the concomitant over the sequential therapy[[44](#_ENREF_44)], though the two regimens have performed equally when compared using 338 patients in a high antibiotic resistance country (Spain)[[45](#_ENREF_45)]. Indeed, by evaluating 106 patients with pre-treatment susceptibility testing, the concomitant therapy eradicated only 55% of dual-resistant strains *vs* 100% and 91% with CAM and MNZ resistance respectively[[46](#_ENREF_46)]. Thus, both regimens seem to be prone to the deleterious impact of dual resistance, performing comparably (with about 81% of efficacy each) by pooling data of 6 comparative RCTs[[38](#_ENREF_38)].

**HYBRID THERAPY**

A two-step dual-concomitant (hybrid) regimen, proposed by Hsu *et al*[[47](#_ENREF_47)], is another valuable treatment option competing with both the sequential and concomitant treatments. By evaluating data from 2 RCTs, hybrid therapy performed marginally, though not significantly, better as compared to sequential therapy (86.6% *vs* 81%)[[38](#_ENREF_38)], and comparably to concomitant therapy in a comparative study in which, interestingly, fewer adverse events occurred in the group treated with the hybrid regimen[[43](#_ENREF_43)]. Further data is warranted to allow for definitive conclusions on the efficacy and tolerability of hybrid therapy.

**LEVOFLOXACIN-BASED THERAPIES**

To overcome increasing CAM resistance, levofloxacin, a broad spectrum quinolone, has been used as a substitute of CAM in either triple or sequential regimens achieving > 90% cure rates, and even > 95% is feasible provided that the local resistance to levofloxacin is low (< 10%)[[48](#_ENREF_48), [49](#_ENREF_49)]. However, levofloxacin also encounters clinically significant problems of antibiotic resistance, as resistance to quinolones currently exceeds 40% in America, 20% in Europe and 10% in Asia[[8](#_ENREF_8)]. Due to the rapid development of secondary quinolone resistance, first-line use of levofloxacin is generally discouraged, and the drug is reserved for use in second-line/rescue regimens after failure of a CAM- and/or a MNZ-based regimen[[50](#_ENREF_50)]. The good (cure rates 81%-87%) second-line efficacy of a levofloxacin triple therapy (LTT) has been confirmed in two meta-analyses published in 2006, both showing better results with LTT in comparison with second-line BQT[[51](#_ENREF_51), [52](#_ENREF_52)]. Congruently, second-line efficacy of LTT was 88.7% in a more recent meta-analysis including RCTs up to October 2010[[53](#_ENREF_53)]. Critically, use of LTT after failure of either a sequential or concomitant regimen has been reported to provide up to 97.8% of cumulative therapeutic efficacy[[54](#_ENREF_54)]. Use of other quinolone agents, such as Moxifloxacin and Sitafloxacin, has shown promising results[[55](#_ENREF_55), [56](#_ENREF_56)], though there is no evidence to support any therapeutic advantage over levofloxacin.

**FUTURE PERSPECTIVES**

***Adjunct probiotics***

Albeit different attempts have been made to restore the efficacy of standard treatments, such as increasing the PPI dose or prolonging treatment duration, none has been proved at a level to overcome today’s antimicrobial resistance. An approach which has attracted growing interest is using probiotics in conjunction with regimens to eradicate *H. pylori*[[57](#_ENREF_57)]. The expected benefit is twofold: boosting eradication and improving tolerability by preventing occurrence of treatment-related side effects. The pathogenic basis of a possible beneficial effect of probiotics on *H. pylori* eradication remains to be clarified, though some hypothesis have been put forward including strength of the mucosal barrier, competition for adhesion and immunomodulatory mechanisms[[58](#_ENREF_58)]. Different trials used probiotics adjunctively to either standard or novel regimens in recent years providing contradictory results[[59-62](#_ENREF_59)]. Although different single- or multi-strain compounds have been evaluated, there is currently evidence to support use of *Saccharomyces boulardi* (OR = 1.13; 95%CI: 1.05-1.21) or *Lactobacillus spp.* (OR = 1.78; 95%CI: 1.2-2.6) supplementation adjunctively to standard triple therapy[[63](#_ENREF_63), [64](#_ENREF_64)]. In the most recent analysis assessing the effect of Lactobacillus-containing and Bifidobacterium-containing supplementation, the pooled odds ratio (ITT) with probiotic supplementation was 2.066 (95%CI: 1.398-3.055) for eradication and 0.305 (95%CI: 0.117-0.793) for the incidence of total side effects[[65](#_ENREF_65)]. Interestingly, with respect to the prevention of side-effects, use of probiotics may be relevant only in a subset of patients, in particularly those with recurrent infection or history of gastrointestinal antibiotic-related side effects[[57](#_ENREF_57)]. Further data is awaited to clarify the role, standardize regimens and assess the cost-effectiveness of probiotics in the treatment of *H. pylori* infection.

***Culture-free, non-invasive determination of H. pylori antibiotic susceptibility***

Critically, even the novel treatments discussed above are to some (although to a lesser as compared to legacy therapies) degree prone to the impact of antibiotic resistance; eradication rates > 95% are infrequent, and even > 90% are disputed in some studies[[35](#_ENREF_35), [66](#_ENREF_66), [67](#_ENREF_67)]. Furthermore, it is possible that the success of empirical treatments will further decline in the future as resistance to key antibiotics is constantly growing worldwide. In order to maintain high therapeutic efficacy, tailored treatment of *H. pylori* in*f*ection based on pre-treatment susceptibility testing appears as the ideal approach. This will prevent exposing the patient to repeated empirical treatments which increase the risk for side effects and promote development of secondary resistance. However, as mentioned, current means of performing endoscopy and *H. pylori* culture are invasive, do not 100% reflect in vivo susceptibility, and are time-consuming as culture requires 3-10 d and susceptibility testing (eg by Etest, AB bioMerieux, Solna, Sweden) will require additional 3-4 d. These limitations preclude systematical performance of *H. pylori* culture, which is currently recommended only for cases with at least two empirical treatment failures. A class-wide resistance to macrolides is the result of point mutations in three adjacent nucleotide positions (*A2143G, A2142G and A2142C*) in the peptidyl tranfserase loop of the *23S*rRNA gene[[68](#_ENREF_68), [69](#_ENREF_69)]. These three point mutations account for 90% of cases of primary CAM resistance in Western countries. In recent years, molecular testing methods have been developed for these mutations including a standard Polymerase Chain Reaction (PCR) and other PCR-based methods including PCR-restriction fragment length polymorphism (RFLP), PCR-DNA enzyme immunoassay (DEIA), PCR oligonucleotide ligation assay (OLA) and PCR-line probe assay, as well as Real-time PCR assay which represents a powerful advancement of the basic PCR[[70-72](#_ENREF_70)]. These methods may offer rapid and highly accurate results in the genotypic detection of CAM resistance, including detection of the heteroresistant status (*i.e*., co-existence of strains susceptible and resistant to the same antibiotic) known to account for a significant number of treatment failures[[73](#_ENREF_73), [74](#_ENREF_74)]. These techniques can be directly applied on gastric biopsy specimens or used in association with minimally-invasive techniques (*e.g.,* oro-gastric brushing or gastric wash) or non-invasively using stool specimens [[75-77](#_ENREF_75)]. Importantly, genotypic detection of CAM resistance is also possible with Fluorescence In-Situ Hybridization (FISH), which can be also applied on paraffin-embedded specimens[[78](#_ENREF_78), [79](#_ENREF_79)]. Detection of levofloxacin resistance based on the detection of *gyrA* mutations is also available[[80](#_ENREF_80)]. Two Asian studies have provided data on the potential utility of a tailored therapeutic approach based on the molecular detection of *H. pylori* resistance to CAM. Tailored treatment using a simple PPI/MNZ regimen successfully eradicated the pathogen in 94.3% *vs* 71.4% using empirical standard treatment[[77](#_ENREF_77)]. In a larger study (218 patients), CAM was replaced by MNZ in the triple regimen if a CAM-resistant strain was detected. Eradication rates were 91.2% in the tailored group *vs* 79.1% and 75.9% by using empirical MNZ- and CAM-based triple therapies (*n* = 308 in each control group) respectively (*P* < 0.001)[[81](#_ENREF_81)].

***Pharmacogenomics***

Genetic variability in the activity of the cytochrome P450 (CYP) 2C19 (CYP2C19) is known to influence the plasma levels of PPIs, and thus treatment of *H. pylori* infection[[82](#_ENREF_82), [83](#_ENREF_83)]. Three distinct genotypes are recognized: rapid, intermediate and poor metabolizers. Preliminary data on the potential use of pharmacogenomics has been provided by a RCT with 300 *H. pylori*-positive patients randomized to either a 1 wk standard regimen or to personalized therapy based on both CYP2C19 and CAM susceptibility status assessed by genetic testing[[84](#_ENREF_84)]. The ITT eradication rates were significantly higher in the tailored group (96% *vs* 70%) without an increase of the final per-patient cost for successful eradication. In the future, both practical and logistic issues should be addressed before a molecular-based approach can be widely adopted as a genuine basis for the individualization of *H. pylori* eradication therapies.

**CONCLUSION**

For more than a decade, triple regimens have been the standard of care therapies for *H. pylori* infection. However, in more recent years, rising prevalence of macrolide resistance has accounted for a significant decline in the performance of these regimens, resulting in the necessity of more treatment courses in order to eradicate the pathogen. In order to maintain high therapeutic efficacy, regimens with an improved performance against antibiotic-resistant *H. pylori* strains are now recommended as preferred first-line treatments. The concomitant and sequential regimens are currently the best validated first-line therapeutic options. Hybrid therapy is another effective CAM-based alternative and a relevant competitor to both these treatments. BQT is also a valid treatment for high CAM resistance settings, but also an effective second-line regimen when a CAM-based regimen fails. Due to the rapid development of quinolone resistance, levofloxacin-based regimens should be currently reserved as second-or-more-line treatment options. While efforts to improve empirical treatments continue, the fields of genotypic detection of *H. pylori* antimicrobial susceptibility and pharmacogenomics offer a fascinating new perspective. This is to guarantee 100% therapeutic efficacy: fast, culture-free and non-invasive.

**REFERENCES**

1 **Moayyedi P**, Hunt RH. Helicobacter pylori public health implications. *Helicobacter* 2004; **9 Suppl 1**: 67-72 [PMID: 15347308 DOI: 10.1111/j.1083-4389.2004.00250.x]

2 **Malfertheiner P**, Chan FK, McColl KE. Peptic ulcer disease. *Lancet* 2009; **374**: 1449-1461 [PMID: 19683340 DOI: 10.1016/S0140-6736(09)60938-7]

3 **Kuipers EJ**. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. *Aliment Pharmacol Ther* 1997; **11 Suppl 1**: 71-88 [PMID: 9146793]

4 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

5 **Gisbert JP**. Is culture necessary before first-line treatment for Helicobacter pylori infection? *Intern Med* 2011; **50**: 2717; author reply 2719-2720 [PMID: 22041399 DOI: JST.JSTAGE/internalmedicine/50.5135]

6 **Mégraud F**. H pylori antibiotic resistance: prevalence, importance, and advances in testing. *Gut* 2004; **53**: 1374-1384 [PMID: 15306603 DOI: 10.1136/gut.2003.022111]

7 **Fischbach L**, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. *Aliment Pharmacol Ther* 2007; **26**: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]

8 **De Francesco V**, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. *J Gastrointestin Liver Dis* 2010; **19**: 409-414 [PMID: 21188333]

9 **Megraud F**, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013; **62**: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]

10 **Boyanova L**, Ilieva J, Gergova G, Davidkov L, Spassova Z, Kamburov V, Katsarov N, Mitov I. Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study. *J Med Microbiol* 2012; **61**: 85-93 [PMID: 21873378 DOI: 10.1099/jmm.0.035568-0]

11 **Georgopoulos SD**, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, Raptis SA. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin. *Dig Dis Sci* 2000; **45**: 63-67 [PMID: 10695615]

12 **Yang JC**, Lin CJ. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection. *Expert Opin Drug Metab Toxicol* 2010; **6**: 29-41 [PMID: 19968574 DOI: 10.1517/17425250903386251]

13 **George LL**, Borody TJ, Andrews P, Devine M, Moore-Jones D, Walton M, Brandl S. Cure of duodenal ulcer after eradication of Helicobacter pylori. *Med J Aust* 1990; **153**: 145-149 [PMID: 1974027]

14 **Bazzoli F**, Pozzato P. Therapy of H. pylori infection. *J Physiol Pharmacol* 1997; **48 Suppl 4**: 39-46 [PMID: 9440054]

15 Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. *Gut* 1997; **41**: 8-13 [PMID: 9274464]

16 **Lind T**, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdörffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idström JP. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. *Helicobacter* 1996; **1**: 138-144 [PMID: 9398894]

17 **Malfertheiner P**, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002; **16**: 167-180 [PMID: 11860399]

18 **Malfertheiner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]

19 **Chey WD**, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]

20 **Fock KM**, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; **24**: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]

21 **Venerito M**, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. *Digestion* 2013; **88**: 33-45 [PMID: 23880479 DOI: 10.1159/000350719]

22 **Houben MH**, van de Beek D, Hensen EF, de Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. *Aliment Pharmacol Ther* 1999; **13**: 1047-1055 [PMID: 10468680 DOI: apt555]

23 **Graham DY**, Qureshi WA. Antibiotic-resistant H. pylori infection and its treatment. *Curr Pharm Des* 2000; **6**: 1537-1544 [PMID: 10974150]

24 **Fischbach LA**, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. *Aliment Pharmacol Ther* 2004; **20**: 1071-1082 [PMID: 15569109 DOI: 10.1111/j.1365-2036.2004.02248.x]

25 **de Boer WA**, van Etten RJ, Schneeberger PM, Tytgat GN. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. *Am J Gastroenterol* 2000; **95**: 641-645 [PMID: 10710051 DOI: 10.1111/j.1572-0241.2000.01971.x]

26 **Laine L**, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. *Am J Gastroenterol* 2003; **98**: 562-567 [PMID: 12650788 DOI: S0002927002060100]

27 **Malfertheiner P**, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. *Lancet* 2011; **377**: 905-913 [PMID: 21345487 DOI: S0140-6736(11)60020-2]

28 **Luther J**, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol* 2010; **105**: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]

29 **Gisbert JP**. Rescue Therapy for Helicobacter pylori Infection 2012. *Gastroenterol Res Pract* 2012; **2012**: 974594 [PMID: 22536225 DOI: 10.1155/2012/974594]

30 **Gisbert JP**, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. *Dig Dis Sci* 2014; **59**: 383-389 [PMID: 24126798 DOI: 10.1007/s10620-013-2900-x]

31 **Ford AC**, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. *World J Gastroenterol* 2008; **14**: 7361-7370 [PMID: 19109870]

32 **Webber MA**, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. *J Antimicrob Chemother* 2003; **51**: 9-11 [PMID: 12493781]

33 **Zullo A**, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi V, Perri F, Papadìa C, Fornari F, Pilati S, Mete LS, Merla A, Potì R, Marinone G, Savioli A, Campo SM, Faleo D, Ierardi E, Miglioli M, Morini S. High eradication rates of Helicobacter pylori with a new sequential treatment. *Aliment Pharmacol Ther* 2003; **17**: 719-726 [PMID: 12641522 DOI: 1461]

34 **Gisbert JP**, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. *J Clin Gastroenterol* 2010; **44**: 313-325 [PMID: 20054285 DOI: 10.1097/MCG.0b013e3181c8a1a3]

35 **Greenberg ER**, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. *Lancet* 2011; **378**: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]

36 **Lim JH**, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. *Helicobacter* 2013; **18**: 180-186 [PMID: 23305083 DOI: 10.1111/hel.12034]

37 **Sardarian H**, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. *Helicobacter* 2013; **18**: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]

38 **Gatta L**, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; **347**: f4587 [PMID: 23926315 DOI: 10.1136/bmj.f4587]

39 **Georgopoulos S**, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. *J Clin Gastroenterol* 2013; **47**: 228-232 [PMID: 22858517 DOI: 10.1097/MCG.0b013e31826015b0]

40 **Georgopoulos S**, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. *Helicobacter* 2012; **17**: 49-53 [PMID: 22221616 DOI: 10.1111/j.1523-5378.2011.00911.x]

41 **Gisbert JP**, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. *Clin Exp Gastroenterol* 2012; **5**: 23-34 [PMID: 22457599 DOI: 10.2147/CEG.S25419]

42 **Essa AS**, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. *Helicobacter* 2009; **14**: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x]

43 **Molina-Infante J**, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013; **145**: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]

44 **Wu DC**, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. *Clin Gastroenterol Hepatol* 2010; **8**: 36-41.e1 [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030]

45 **McNicholl AG**, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014; **63**: 244-249 [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820]

46 **Georgopoulos SD**, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. *Helicobacter* 2013; **18**: 459-467 [PMID: 23714140 DOI: 10.1111/hel.12062]

47 **Hsu PI**, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. *Helicobacter* 2011; **16**: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]

48 **Romano M**, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. *Gut* 2010; **59**: 1465-1470 [PMID: 20947881 DOI: 10.1136/gut.2010.215350]

49 **Berning M**, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? *Therap Adv Gastroenterol* 2011; **4**: 103-114 [PMID: 21694812 DOI: 10.1177/1756283X10384171]

50 **Carothers JJ**, Bruce MG, Hennessy TW, Bensler M, Morris JM, Reasonover AL, Hurlburt DA, Parkinson AJ, Coleman JM, McMahon BJ. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. *Clin Infect Dis* 2007; **44**: e5-e8 [PMID: 17173210 DOI: 10.1086/510074]

51 **Gisbert JP**, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. *Aliment Pharmacol Ther* 2006; **23**: 35-44 [PMID: 16393278 DOI: 10.1111/j.1365-2036.2006.02737.x]

52 **Saad RJ**, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. *Am J Gastroenterol* 2006; **101**: 488-496 [PMID: 16542284 DOI: 10.1111/j.1572-0241.1998.455\_t.x]

53 **Di Caro S**, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, Di Renzo L, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. *World J Gastroenterol* 2012; **18**: 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669]

54 **Gisbert JP**, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. *Scand J Gastroenterol* 2013; **48**: 652-656 [PMID: 23556551 DOI: 10.3109/00365521.2013.786132]

55 **Murakami K**, Okimoto T, Kodama M, Tanahashi J, Fujioka T, Ikeda F, Muraoka H, Takigawa M, Saika T, Hasegawa M, Kobayashi I. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. *Antimicrob Agents Chemother* 2009; **53**: 3097-3099 [PMID: 19380599 DOI: 10.1128/AAC.01552-08]

56 **Wenzhen Y**, Kehu Y, Bin M, Yumin L, Quanlin G, Donghai W, Lijuan Y. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. *Intern Med* 2009; **48**: 2069-2076 [PMID: 20009394 DOI: JST.JSTAGE/internalmedicine/48.2344]

57 **Wilhelm SM**, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. *Ann Pharmacother* 2011; **45**: 960-966 [PMID: 21693698 DOI: 10.1345/aph.1Q104]

58 **Lesbros-Pantoflickova D**, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. *J Nutr* 2007; **137**: 812S-818S [PMID: 17311980 DOI: 137/3/812S]

59 **Du YQ**, Su T, Fan JG, Lu YX, Zheng P, Li XH, Guo CY, Xu P, Gong YF, Li ZS. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. *World J Gastroenterol* 2012; **18**: 6302-6307 [PMID: 23180952 DOI: 10.3748/wjg.v18.i43.6302]

60 **Efrati C**, Nicolini G, Cannaviello C, O'Sed NP, Valabrega S. Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. *World J Gastroenterol* 2012; **18**: 6250-6254 [PMID: 23180945 DOI: 10.3748/wjg.v18.i43.6250]

61 **Manfredi M**, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. *Helicobacter* 2012; **17**: 254-263 [PMID: 22759324 DOI: 10.1111/j.1523-5378.2012.00944.x]

62 **Shavakhi A**, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. *Helicobacter* 2013; **18**: 280-284 [PMID: 23433200 DOI: 10.1111/hel.12047]

63 **Szajewska H**, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. *Aliment Pharmacol Ther* 2010; **32**: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]

64 **Zou J**, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. *Helicobacter* 2009; **14**: 97-107 [PMID: 19751434 DOI: 10.1111/j.1523-5378.2009.00716.x]

65 **Wang ZH**, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. *J Clin Gastroenterol* 2013; **47**: 25-32 [PMID: 23090045 DOI: 10.1097/MCG.0b013e318266f6cf]

66 **Liou JM**, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *Lancet* 2013; **381**: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]

67 **Vakil N**, Vaira D. Treatment for H. pylori infection: new challenges with antimicrobial resistance. *J Clin Gastroenterol* 2013; **47**: 383-388 [PMID: 23388847 DOI: 10.1097/MCG.0b013e318277577b]

68 **Taylor DE**, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. *Antimicrob Agents Chemother* 1997; **41**: 2621-2628 [PMID: 9420030]

69 **Versalovic J**, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. *Antimicrob Agents Chemother* 1996; **40**: 477-480 [PMID: 8834903]

70 **Lehours P**, Siffré E, Mégraud F. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. *BMC Gastroenterol* 2011; **11**: 112 [PMID: 22004003 DOI: 10.1186/1471-230X-11-112]

71 **Mégraud F**, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. *Clin Microbiol Rev* 2007; **20**: 280-322 [PMID: 17428887 DOI: 10.1128/CMR.00033-06]

72 **Schabereiter-Gurtner C**, Hirschl AM, Dragosics B, Hufnagl P, Puz S, Kovách Z, Rotter M, Makristathis A. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. *J Clin Microbiol* 2004; **42**: 4512-4518 [PMID: 15472302 DOI: 10.1128/JCM.42.10.4512-4518.2004]

73 **De Francesco V**, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Panella C, Vaira D. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. *J Antimicrob Chemother* 2010; **65**: 327-332 [PMID: 20008044 DOI: 10.1093/jac/dkp445]

74 **Rimbara E**, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. *Nat Rev Gastroenterol Hepatol* 2011; **8**: 79-88 [PMID: 21293508 DOI: 10.1038/nrgastro.2010.210]

75 **Baba S**, Oishi Y, Watanabe Y, Oikawa R, Morita R, Yoshida Y, Hiraishi T, Maehata T, Nagase Y, Fukuda Y, Nakazawa M, Ishigouoka S, Hattori N, Suzuki H, Toyota M, Niwa H, Suzuki M, Itoh F. Gastric wash-based molecular testing for antibiotic resistance in Helicobacter pylori. *Digestion* 2011; **84**: 299-305 [PMID: 22057261 DOI: 10.1159/000332570]

76 **Graham DY**, Kudo M, Reddy R, Opekun AR. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. *Helicobacter* 2005; **10**: 1-3 [PMID: 15691309 DOI: 10.1111/j.1523-5378.2005.00285.x]

77 **Kawai T**, Yamagishi T, Yagi K, Kataoka M, Kawakami K, Sofuni A, Itoi T, Sakai Y, Moriyasu F, Osaka Y, Takagi Y, Aoki T, Rimbara E, Noguchi N, Sasatsu M. Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities. *J Gastroenterol Hepatol* 2008; **23 Suppl 2**: S171-S174 [PMID: 19120893 DOI: 10.1111/j.1440-1746.2008.05408.x]

78 **Morris JM**, Reasonover AL, Bruce MG, Bruden DL, McMahon BJ, Sacco FD, Berg DE, Parkinson AJ. Evaluation of seaFAST, a rapid fluorescent in situ hybridization test, for detection of Helicobacter pylori and resistance to clarithromycin in paraffin-embedded biopsy sections. *J Clin Microbiol* 2005; **43**: 3494-3496 [PMID: 16000488 DOI: 10.1128/JCM.43.7.3494-3496.2005]

79 **Yilmaz O**, Demiray E, Tümer S, Altungöz O, Yörükoğlu K, Soytürk M, Simşek I. Detection of Helicobacter pylori and determination of clarithromycin susceptibility using formalin-fixed, paraffin-embedded gastric biopsy specimens by fluorescence in situ hybridization. *Helicobacter* 2007; **12**: 136-141 [PMID: 17309750 DOI: 10.1111/j.1523-5378.2007.00483.x]

80 **Cambau E**, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. *J Clin Microbiol* 2009; **47**: 3600-3607 [PMID: 19759218 DOI: 10.1128/JCM.00744-09]

81 **Lee HJ**, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH, Kim JK. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. *J Infect Dis* 2013; **208**: 1123-1130 [PMID: 23801607 DOI: 10.1093/infdis/jit287]

82 **Furuta T**, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. *Clin Pharmacol Ther* 2001; **69**: 158-168 [PMID: 11240980 DOI: 10.1067/mcp.2001.113959]

83 **Sim SC**, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther* 2006; **79**: 103-113 [PMID: 16413245 DOI: 10.1016/j.clpt.2005.10.002]

84 **Furuta T**, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, Iwaizumi M, Yamade M, Terakawa I, Ohashi K, Ishizaki T, Hishida A. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. *Clin Pharmacol Ther* 2007; **81**: 521-528 [PMID: 17215846 DOI: 10.1038/sj.clpt.6100043]

**P-Reviewers:** DingSZ, Im SH, Velin D, Zhu YL **S-Editor:** Wen LL

**L-Editor: E-Editor:**

**Table 1 Factors reported to negatively affect the outcome of therapies for *Helicobacter pylori* infection**

|  |  |
| --- | --- |
| **Pathogen-related** | **Host-related** |
| Development of resistance to antibiotics | Non-compliance to treatment |
| High bacterial load in the stomach | Non-ulcer dyspepsia |
| Protective effect of the gastric mucus layer | Smoking |
| Intracellular location of many bacteria | CYP2C19 status (rapid metabolizer) |
| *CagA* negative  |  |
| Presence of dormant coccoid forms (not susceptible to antibiotics) |  |
| Heteroresistant status (co-existence of strains susceptible and resistant to the same antibiotic) |  |

**Table 2 Current regimens to treat *Helicobacter pylori* infection**

|  |  |
| --- | --- |
| **Treatment**  | **Regimen** |
| Bismuth-containing quadruple therapy | A PPI (standard dose, *bid*), bismuth (standard dose, *qid*) tetracycline (500 mg, *qid*) and metronidazole (500 mg, *qid*) for 10-14 d |
| Sequential therapy | A 5-d dual therapy with a PPI (standard dose, *bid*) and amoxicillin (1 g, *bid*) followed by a 5-d triple therapy with a PPI (standard dose, *bid*), clarithromycin (500 mg, *bid*) and metronidazole (500 mg, *bid*) |
| Concomitant therapy | A PPI (standard dose, *bid*), clarithromycin (500 mg, *bid*), amoxicillin (1 g, *bid*) and metronidazole (500 mg, *bid*) for 7-10 d |
| Hybrid therapy | A 7-day dual therapy with a PPI (standard dose, *bid*) and amoxicillin (1 g, *bid*) followed by a 7-day quadruple therapy with a PPI (standard dose, *bid*), amoxicillin (1 g, *bid*), clarithromycin (500 mg, *bid*) and metronidazole (500 mg, *bid*) |
| Levofloxacin-based triple therapy | A PPI (standard dose, *bid*), levofloxacin (500 mg, *bid*) and amoxicillin (1 g, *bid*) for 10 d |

PPI: Proton pump inhibitor.